摘要
目的:观察纳美芬治疗慢性Ⅱ型呼吸衰竭的疗效。方法:40例慢性Ⅱ型呼吸衰竭患者随机分为治疗组与对照组。在常规治疗基础上,治疗组用纳美芬1.0mg加入5%葡萄糖盐水250mL中静脉滴注,每日1次;对照组用尼可刹米1.875g加入5%葡萄糖盐水250mL中缓慢静脉滴注,每日1次。2组疗程均为5d。观察临床症状、体征变化,记录不良反应发生情况,检测肺功能、血气分析指标。结果:治疗组与对照组总有效率分别为95.0%、60.0%(P<0.05);治疗后治疗组肺功能、血气分析检测指标的改善明显优于对照组(P<0.05)。2组均未发生明显不良反应。结论:纳美芬治疗慢性Ⅱ型呼吸衰竭安全、有效,值得临床推广应用。
OBJECTIVE： To study the clinical efficacy of Nalmefene in the treatment of chronic type Ⅱ respiratory failure. METHODS： A total of 40 patients with chronic type Ⅱ respiratory failure were randomly divided into treatment group and the control group： the treatment group received Nalmefene （1.0 mg） plus 5% GS （250 mL） q.d by iv gtt. in addition to the routine treatment, and the control group received 1.875 g Nikethamide plus 5% GS （250 mL） q.d by iv gtt. After 5-day treatment, the clinical symptom, physical signs, adverse drug reactions, lung function testing and blood gas analysis in two groups were evaluated. RESULTS： The overall response rate was 95.0% in the treatment group vs. 60.0% in the control group（P〈0.05） ; the treatment group had significantly better improvement in lung function and blood gas parameters than that in the control group（P〈0.05）. No obvious adverse reactions were noted in both groups. CONCLUSION： Nalmefene is safe and effective for chronic type Ⅱ respiratory failure, thus its clinical use is worthy of recommendation.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第6期525-527,共3页
China Pharmacy
关键词
纳美芬
呼吸衰竭
治疗
Nalmefene
Respiratory failure
Treatment
